First Manhattan
SVA

First Manhattan’s Sinovac Biotech, Ltd SVA Stock Holding History

First Manhattan’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-336,747
Closed -$2M – 1556
2016
Q2 		$2M Sell
336,747
-663,200
-66% -$4.07M 0.01% 345
2016
Q1 		$6.39M Sell
999,947
-32,166
-3% -$193K 0.04% 210
2015
Q4 		$5.9M Hold
1,032,113
– – 0.04% 220
2015
Q3 		$5.24M Buy
1,032,113
+428,447
+71% +$2.27M 0.03% 227
2015
Q2 		$3.17M Buy
+603,666
New +$3.19M 0.02% 303

Other funds holding SVA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
USAA
United Services Automobile Association San Antonio, Texas $1.24B AUM 2.91% 1-Year Est. Return
FIM
Freedom Investment Management Hartford, Connecticut $359M AUM 23.01% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

First Manhattan's SVA Position: Q3 2016 in Review

First Manhattan sold out of Sinovac Biotech, Ltd (SVA) in Q3 2016, closing a stake of 336,747 shares — an estimated $2M sold.

First Manhattan first reported a position in SVA in Q2 2015 and held it in 5 quarters. The position peaked at $6.39M in Q1 2016. 36 funds tracked by Wall St. Rank hold SVA as of Q3 2016.

  • First Manhattan reported no remaining Sinovac Biotech, Ltd position as of Q3 2016 after selling out during the quarter.
  • First Manhattan sold 336,747 Sinovac Biotech, Ltd shares in Q3 2016, an estimated $2M.
  • First Manhattan first reported a position in Sinovac Biotech, Ltd in Q2 2015 and held it in 5 quarters.
  • First Manhattan's Sinovac Biotech, Ltd position peaked at $6.39M in Q1 2016.
  • 36 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2016.

Based on First Manhattan's 13F filing for Q3 2016, filed 20 Oct 2016.